[Warm autoimmune hemolytic anemias and Evans syndrome in adults]
Standard
[Warm autoimmune hemolytic anemias and Evans syndrome in adults]. / Michel, Melanie.
In: REV MED INTERNE, Vol. 29, No. 2, 2, 2008, p. 105-114.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [Warm autoimmune hemolytic anemias and Evans syndrome in adults]
AU - Michel, Melanie
PY - 2008
Y1 - 2008
N2 - PURPOSE: The outcome of autoimmune hemolytic anemia (AIHA) and Evans syndrome (ES) in adults is not well-known and their management is mainly based on empirical data. CURRENT KNOWLEDGE AND KEY POINTS: The main characteristics of both AIHA and ES are reviewed in this article, based on the data available in the literature and on our experience. Although controlled studies and evidence-based data are lacking, some recommendations regarding the minimal workup useful to search for an underlying disease can be made as well as proposals for a better therapeutic strategy of both disorders. FUTURE PROSPECTS AND PROJECTS: A better knowledge of the mechanisms triggering AIHA and ES as well as therapeutic trials are needed in order to better stratify treatment taking into account the promising efficacy of rituximab.
AB - PURPOSE: The outcome of autoimmune hemolytic anemia (AIHA) and Evans syndrome (ES) in adults is not well-known and their management is mainly based on empirical data. CURRENT KNOWLEDGE AND KEY POINTS: The main characteristics of both AIHA and ES are reviewed in this article, based on the data available in the literature and on our experience. Although controlled studies and evidence-based data are lacking, some recommendations regarding the minimal workup useful to search for an underlying disease can be made as well as proposals for a better therapeutic strategy of both disorders. FUTURE PROSPECTS AND PROJECTS: A better knowledge of the mechanisms triggering AIHA and ES as well as therapeutic trials are needed in order to better stratify treatment taking into account the promising efficacy of rituximab.
M3 - SCORING: Zeitschriftenaufsatz
VL - 29
SP - 105
EP - 114
JO - REV MED INTERNE
JF - REV MED INTERNE
SN - 0248-8663
IS - 2
M1 - 2
ER -